Actos Now for the prevention of diabetes (ACT NOW) study

BMC Endocrine Disorders

Volumn 9, Issue , 2009, Pages

  DeFronzo, Ralph A ^a   Banerji, Mary Ann ^b   Bray, George A ^c   Buchanan, Thomas A ^d   Clement, Stephen ^e   Henry, Robert R ^f   Kitabchi, Abbas E ^g   Mudaliar, Sunder ^f   Musi, Nicolas ^a   Ratner, Robert ^h   Reaven, Peter D ^i,j   Schwenke, Dawn ^i,j   Stentz, Frankie B ^g   Tripathy, Devjit ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h MEDSTAR RESEARCH INSTITUTE   (United States)

ⁱ CARL T HAYDEN VA MEDICAL CENTER   (United States)

^j ARIZONA STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PREGNANCY TEST; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK REDUCTION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINALYSIS; WAIST CIRCUMFERENCE;

EID: 68949207969     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-9-17     Document Type: Article

References (44)

1. Cowie CC Rust KF Byrd-Holt DD Eberhardt MS Flegal KM Engelgau MM Saydah SH Williams DE Geiss LS Gregg EW Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002 Diabetes Care 2006, 29:1263-1268 10.2337/dc06-0062 16732006
2. Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004, 27:1047-1053 10.2337/diacare.27.5.1047 15111519
3. World Health Organization Diabetes Programme Facts and Figures, 2007 World Health Organisation; Geneva, Switzerland http://www.who.int/ diabetes/facts/en/
4. UK Prospective Diabetes Study Group Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37) Diabetes Care 1999, 22:1125-1136 10.2337/diacare.22.7.1125 10388978
5. Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Hadden D Turner RC Holman RR Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications on type 2 dia betes (UKPDS 35): Prospective observational study BMJ 2000, 321:405-412 10.1136/bmj.321.7258.405 27454 10938048
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998:837-853
7. Klein R Barrett-Connor EL Blunt BA Wingard DL Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance, and newly diagnosed NIDDM Diabetes Care 1991, 14:914-918 10.2337/diacare.14.10.914 1773692
8. Shichiri M Kishikawa H Ohkubo Y Wake N Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients Diabetes Care 2000, 23(Suppl 2):B21-29 10860187
9. American Diabetes Association Economic costs of diabetes in the US in 2007 Diabetes Care 2008, 31:1-20 10.2337/dc08-S001
10. DeFronzo RA Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM Diabetes 1988, 37:667-687 3289989
11. Weyer C Bogardus C Mott DM Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 1999, 104:787-794 10.1172/JCI7231 408438 10491414
12. Festa A Williams K D'Agostino R Jr Wagenknecht LE Haffner SM The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study Diabetes 2006, 55:1114-1120 10.2337/diabetes.55.04.06.db05-1100 16567536
13. Lyssenko V Almgren P Anevski D Perfekt R Lahti K Nissen M Isomaa B Forsen B Homstrom N Saloranta C Taskinen MR Groop L Tuomi T Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes Diabetes 2005, 54:166-174 10.2337/ diabetes.54.1.166 15616025
14. Xiang AH Peters RK Kjos SL Marroquin A Goico J Ochoa C Kawakubo M Buchanan TA Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes Diabetes 2006, 55:517-522 10.2337/diabetes.55.02.06.db05-1066 1389697 16443789
15. Tuomilehto J Lindstrom J Eriksson JG Valle TT Hamalainen H Ilanne-Parikka P Keinanen-Kiukaanniemi S Laakso M Louheranta A Rastas M Salminen V Uusitupa M Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 2001, 344:1343-1350 10.1056/NEJM200105033441801 11333990
16. Knowler WC Barrett-Connor E Fowler SE Hamman RF Lachin JM Walker EA Nathan DM Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002, 346:393-403 10.1056/ NEJMoa012512 1370926 11832527
17. Gerstein HC Yusuf S Bosch J Pogue J Sheridan P Dinccag N Hanefeld M Hoogwerf B Laakso M Mohan V Shaw J Zinman B Holman RR Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial Lancet 2006, 368:1096-1105 10.1016/S0140-6736(06)69829-2 16997664
18. Buchanan TA Xiang AH Peters RK Kjos SL Marroquin A Goico J Ochoa C Tan S Berkowitz K Hodis HN Azen SP Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women Diabetes 2002, 51:2796-2803 10.2337/diabetes.51.9.2796 12196473
19. Gillies CL Abrams KR Lambert PC Cooper NJ Sutton AJ Hsu RT Khunti K Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis BMJ 2007, 334:299-308 10.1136/bmj.39063.689375.55 1796695 17237299
20. Ferrannini E Gastaldelli A Miyazaki Y Matsuda M Mari A DeFronzo RA Beta cell function in subjects spanning the range from normal glucose tolerance to over diabetes: A new analysis J Clin Endocrinol Metab 2005, 90:493-500 10.1210/jc.2004-1133 15483086
21. Abdul-Ghani MA Jenkinson CP Richardson DK Tripathy D DeFronzo RA Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: Results from the Veterans Administration Genetic Epidemiology Study Diabetes 2006, 55:1430-1435 10.2337/db05-1200 16644701
22. Abdul-Ghani A Tripathy D DeFronzo RA Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose Diabetes Care 2006, 29:1130-1139 10.2337/dc05-2179 16644654
23. Miyazaki Y Mahankali A Matsuda M Glass L Mahankali S Ferrannini E Cusi K Mandarino LJ DeFronzo RA Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 2001, 24:710-719 10.2337/diacare.24.4.710 11315836
24. Miyazaki Y He H Mandarino LJ DeFronzo RA Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients Diabetes 2003, 52:1943-1950 10.2337/diabetes.52.8.1943 12882909
25. Kim YB Ciaraldi TP Kong A Kim D Chu N Mohideen P Mudaliar S Henry RR Kahn BB Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110 beta protein levels in skeletal muscle of type 2 diabetic subjects Diabetes 2002, 51:443-448 10.2337/diabetes.51.2.443 11812753
26. Maggs DG Buchanan TA Burant CF Cline G Gumbiner B Hsueh WA Inzucchi S Kelley D Nolan J Olefsky JM Polonsky KS Silver D Valiquett TR Shulman GI Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial Ann Intern Med 1998, 128:176-185 9454525
27. Gastaldelli A Ferrannini E Miyazaki Y Matsuda M Mari A DeFronzo RA Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab 2007, 292:E871-883 10.1152/ ajpendo.00551.2006 17106061
28. Kahn SE Haffner SM Heise MA Herman WH Holman RR Jones NP Kravitz BG Lachin JM O'Neill MC Zinman B Viberti G Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006, 355:2427-2443 10.1056/NEJMoa066224 17145742
29. American Diabetes Association Diagnosis and Classification of Diabetes Diabetes Care 2008, 31:S55-S60 10.2337/dc08-S055 18165338
30. Roberts LJ 2nd Morrow JD The generation and actions of isoprostanes Biochim Biophys Acta 1997, 1345:121-135 9106492
31. Papamichael CM Lekakis JP Stamatelopoulos KS Papaioannou TG Alevizaki MK Cimponeriu AT Kanakakis JE Papapanagiotou A Kalofoutis AT Stamatelopoulos SF Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease Am J Cardiol 2000, 86:615-618 10.1016/ S0002-9149(00)01038-9 10980210
32. Bergman RN Toward physiologic understanding of glucose tolerance Diabetes 1989, 38:1512-1517 10.2337/diabetes.38.12.1512 2684710
33. Hodis HN Mack WJ Barth J Carotid intima-media thickness as a surrogate end point for coronary artery disease Circulation 1996, 94:2311-2312 8901695
34. Van Cauter E Mestrez F Sturis J Polonsky KS Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance Diabetes 1992, 41:368-377 10.2337/diabetes.41.3.368 1551497
35. Gastaldelli A Ferrannini E Miyazaki Y Matsuda M DeFronzo RA Beta cell dysfunction and glucose intolerance: Results from the San Antonio Metabolism (SAM) study Diabetologia 2004, 47:31-39 10.1007/ s00125-003-1263-9 14666364
36. Matsuda M DeFronzo RA Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic glucose clamp Diabetes Care 1999, 22:1462-1470 10.2337/diacare.22.9.1462 10480510
37. Mathews D Hosker J Rudenski A Naylor B Treacher D Turner R Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man Diabetologia 1985, 28:412-419 10.1007/BF00280883 3899825
38. Groop LC Bonadonna RC Shank M Petrides AS DeFronzo RA Role of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man J Clin Invest 1991, 87:83-89 10.1172/JCI115005 294996 1985114
39. Peduzzi P Wittes J Detre K Holford T Analysis as-randomized and the problem of non-adherence: An example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery Statistics in Medicine 1993, 12:1185-1195 10.1002/sim.4780121102 8210821
40. Kalbfleisch JD Prentice RL The Statistical Analysis of Failure Time Data New York: John Wiley 1980
41. Lachin JM Wei LJ Estimators and tests in the analysis of multiple nonindependent 2 × 2 tables with partially missing observations Biometrics 1988, 44:513-528 10.2307/2531864 3291958
42. The Diabetes Prevention Program Research Group The Diabetes Prevention Program: Baseline characteristics of the randomized cohort Diabetes Care 2000, 23:1619-1629 10.2337/diacare.23.11.1619 1360735 11092283
43. Edelstein SL Knowler WC Bain RP Andres R Barrett-Connor EL Dowse GK Haffner SM Pettitt DJ Sorking JD Muller DC Collins VR Hamman RF Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies Diabetes 1997, 46:701-710 10.2337/ diabetes.46.4.701 2517225 9075814
44. Azen SP Peters RK Berkowitz K Kjos S Xiang AN Buchanan TA for the TRIPOD Study Group TRIPOD (TRoglitazone In the Prevention Of Diabetes): A randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus Controlled Clin Trials 1998, 19:217-231 10.1016/S0197-2456(97)00151-7 9551285